NASDAQ · Health care

Revelation Biosciences, Inc. (REVB)

It posted a net loss of $10.8M. At June 30, 2026 it held $11.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.

Price

$0.87

0.00% on the day · September 25, 2026

52-week range $0.85 to $6.76

Market cap

$3.5M

What Revelation Biosciences, Inc. does

Revelation Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker REVB.

Revenue and profit by year

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$9.1M	-$8.9M	-$23.95	n/a
2024	n/a	-$8M	-$15M	-$1,052.16	-$18.3M
2023	n/a	-$8.7M	-$120.3K	-$101.28	n/a
2022	n/a	-$10.9M	-$10.8M	-$28,511.28	n/a
2021	n/a	-$12M	-$12M	-$60,315.04	-$11.2M
2020	n/a	n/a	-$1.6M	-$965.04	n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 5, 2026.

Estimated from its filing rhythm: about 91 days after its last report of August 6, 2026, its usual gap. Not a date the company has announced. See the report calendar

Latest SEC filings

What Revelation Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 19, 2026
Executive or director change 8-K
August 14, 2026
Passive stake changed SCHEDULE 13G/A
August 6, 2026
Quarterly results 8-K
August 6, 2026
Quarterly report 10-Q · period to June 30, 2026Diluted EPS -$0.87 versus -$28.04.
July 13, 2026
Material agreement 8-K
June 24, 2026
Executive or director change 8-K
June 1, 2026
Other event 8-K
May 15, 2026
Passive stake (5% or more) SCHEDULE 13G
May 11, 2026
Proxy statement DEF 14A
May 11, 2026
Annual report to shareholders ARS

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 18, 2026. Insider transactions on SEC

Insider trades

What the people running Revelation Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 7 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

Bought (open market)

last 90 days

Sold

last 90 days

Date	Insider	What	Shares	Price	Value	Filing
August 17, 2026	Carver JenniferDirector	Received as pay	32,011	-	-	Form 4
August 17, 2026	Roper JessDirector	Received as pay	32,011	-	-	Form 4
August 17, 2026	Zygmont Chester Stanley IIIChief Financial Officer	Received as pay	208,073	-	-	Form 4
August 17, 2026	Zygmont Chester Stanley IIIChief Financial Officer	Gave as a gift	208,073	-	-	Form 4
August 17, 2026	Zygmont Chester Stanley IIIChief Financial Officer	Gave as a giftindirect	208,073	-	-	Form 4
August 17, 2026	Chawla Lakhmir SDirector	Received as pay	32,011	-	-	Form 4
August 17, 2026	Rolke JamesChief Executive Officer, Director	Received as pay	208,076	-	-	Form 4
April 30, 2026	Zygmont Chester Stanley IIIChief Financial Officer	Shares withheld for taxindirect	13,285	$1.10	$14.6K	Form 4
April 30, 2026	Rolke JamesChief Executive Officer, Director	Shares withheld for tax	10,115	$1.13	$11.4K	Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns REVB

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

No holder of 5% or more has filed about this company in that window.

Latest filings below 5%: Armistice Capital, LLC 4.99% (August 14, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

5 insiders reported holding 856,727 shares in total, about $745.5K at the last price.

Holder	Shares	As of
Rolke JamesChief Executive Officer, Director	422,814	August 17, 2026
Zygmont Chester Stanley IIIChief Financial Officer	300,136300,136 held indirectly	August 17, 2026
Roper JessDirector	44,839	August 17, 2026
Carver JenniferDirector	44,769	August 17, 2026
Chawla Lakhmir SDirector	44,169	August 17, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about REVB

What does Revelation Biosciences, Inc. do?

Revelation Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker REVB.

Is Revelation Biosciences, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $10.8M.

When did Revelation Biosciences, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the executive or director change from August 19, 2026.

Similar companies

Compare REVB with

Compare REVB with any company

Follow REVB

Get an email when Revelation Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow REVB: get an email when it files

Where the numbers come from

Financial figures are the values Revelation Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.